Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials

BackgroundThe European League of Rheumatology(EULAR)guidelines recommend Janus kinase (JAK) inhibitors for patients with moderate to severe rheumatoid arthritis (RA) who are insensitive or under-responsive to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). But there was no...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Wenting Cai, Rui Tong, Yue Sun, Yao Yao, Jinping Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Subjects:	Janus kinase inhibitors conventional synthetic disease-modifying anti-rheumatic drugs network meta-analysis rheumatoid arthritis efficacy safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1387585/full

Similar Items

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

RUSSIAN AND INTERNATIONAL EXPERIENCE IN THE APPLICATION OF THE JANUS-KINASES INHIBITOR IN RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-05-01)

Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01)

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
by: Sae Ochi, et al.
Published: (2022-03-01)

Rheumatoid factor and anti-cyclic citrullinated peptide antibody levels decline in rheumatoid arthritis patients treated with Janus kinase inhibitors or biological disease-modifying anti-rheumatic drugs
by: Bo Young Kim, et al.
Published: (2025-10-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics
by: Oh Chan Kwon, et al.
Published: (2024-04-01)

Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
by: Haruka Tsuchiya, et al.
Published: (2024-06-01)

Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies
by: Andrei-Flavius Radu, et al.
Published: (2023-06-01)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
by: Jacopo Angelini, et al.
Published: (2020-07-01)

Assessing cardiovascular risk in rheumatoid arthritis patients on Janus kinase inhibitors: real-world data from the European Alliance of Associations for Rheumatology-adapted CUORE risk algorithm
by: Marco Tasso, et al.
Published: (2025-08-01)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
by: Yun-Kyoung Song, et al.
Published: (2023-10-01)

Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment
by: Cristina Martinez-Molina, et al.
Published: (2025-03-01)

Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial
by: Xiaoling Liao, et al.
Published: (2023-10-01)

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes
by: Nina Yao, et al.
Published: (2021-10-01)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023-01-01)

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019-10-01)

Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies
by: Gandy C, et al.
Published: (2025-01-01)

Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors
by: Omair MA, et al.
Published: (2022-10-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01)

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
by: Bong-Woo Lee, et al.
Published: (2024-09-01)

Structural basis of Janus kinase trans-activation
by: Nathanael A. Caveney, et al.
Published: (2023-03-01)

The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors
by: Ana Esteban-Vazquez, et al.
Published: (2023-10-01)

Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study
by: Atsuko Tsujii, et al.
Published: (2024-01-01)

Screening for Janus kinase-2 exon 12 mutations among Janus kinase-2 V617F-negative polycythemia vera suspected Iraqi patients
by: Mushtaq M. Khazeem, et al.
Published: (2024-12-01)

Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data
by: Hong Ki Min, et al.
Published: (2023-04-01)

Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2
by: Zhenghui Song, et al.
Published: (2022-04-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

LATE-ONSET RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB AND LEFLUNOMIDE- A CASE REPORT
by: Tatjana Zekić, et al.
Published: (2024-12-01)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
by: Blanca Hernández-Cruz, et al.
Published: (2023-09-01)

Cervical lymphadenitis caused by Mycobacterium avium in a patient treated with Janus kinase inhibitors
by: Wataru Fujii, et al.
Published: (2023-08-01)

Marine Bioactive Molecules as Inhibitors of the Janus Kinases: A Comparative Molecular Docking and Molecular Dynamics Simulation Approach
by: Emad A. Ahmed, et al.
Published: (2024-09-01)

Management of Rheumatoid Arthritis: An Overview
by: Andrei-Flavius Radu, et al.
Published: (2021-10-01)

MODERN PRINCIPLES OF MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-11-01)

Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
by: Marino Paroli, et al.
Published: (2023-08-01)